Navigation Links
Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology
Date:5/24/2013

Madison, WI (PRWEB) May 24, 2013

Quincy Bioscience, a leading research company committed to the discovery and development of calcium-binding proteins to support healthy living, is pleased to announce publication of safety assessment study of apoaequorin in Food and Chemical Toxicology, an international journal published for the British Industrial Biological Research Association.

The objective of the study was to investigate potential adverse effects, if any, of apoaequorin, in rats following subchronic administration. Based on the results of this study, the No Observed-Adverse-Effect Level (NOAEL) for apoaequorin was determined as 666.7 mg/kg bw/day, the highest dose tested. Administration of the apoaequorin preparation did not result in any mortality. There were no further clinical or opthalmological signs, body weight, body weight gain, food consumption, food efficiency, clinical pathology, or histopathological changes attributable to administration of apoaequorin.

Quincy Bioscience is set apart by its cutting-edge applications of the protein apoaequorin, which is breaking new ground in the area of brain health. Apoaequorin is included in the dietary supplement Prevagen. It is used to improve mild memory loss associated with aging.

To get more information on the study, please visit the journal of Food and Chemical Toxicology. To get more information on apoaequorin, please visit the Prevagen website.

About Quincy Bioscience

Quincy Bioscience is a biotechnology company based in Madison, Wisconsin focused on the discovery, development and commercialization of novel technologies to support good health in aging. The company’s products focus on supporting memory and cognitive health. Quincy Bioscience is set apart by its cutting-edge applications of the protein apoaequorin, which is breaking new ground in the area of brain health.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10765048.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
2. New measuring techniques can improve efficiency, safety of nanoparticles
3. Interim Clinical Trial Results Confirm Safety of Renadyl™, a Probiotic Dietary Supplement for the Support of Healthy Kidney Function
4. Targeted antibacterial agent rapidly created in response to serious food safety pathogen
5. Notre Dame paper examines nanotechnology-related safety and ethics problem
6. New Revolutionary Femoral Access Site Closure Device Shows Unparalleled Efficacy, Safety & Ease of Use, in a Wide Range of Patients Including Patients With a Challenging Anatomy
7. Alliance for Safe Biologic Medicines Chairman Urges FDA to Ensure that Patient Safety is the Cornerstone of Biosimilar Pathway
8. OrbusNeichs Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
9. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
10. New Epidemiological Data Provide Additional Safety Evidence for Lantus®
11. Produce Safety Researchers Awarded by ABC Research Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... LAVAL, QC , Jan. 24, 2017 /PRNewswire/ - ProMetic ... the "Corporation") announced today that its orally active lead ... Medicine ("PIM") designation by the UK Medicines and Healthcare ... Syndrome ("AS"). A PIM designation is ... promising candidate for the Early Access to Medicines Scheme ...
(Date:1/24/2017)... 23, 2017 According to a ... Type (Genetic, Cell-based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoiesis, ... & Biotech Companies, CRO) - Global Forecast to 2021", ... Mouse Model Market for the forecast period of 2016 ... 116.0 Million by 2021 from USD 73.3 Million in ...
(Date:1/23/2017)... NEW YORK , Jan. 23, 2017  Spherix ... development company committed to the fostering of technology and ... its active patent infringement lawsuits. Anthony ... we enter 2017, we will continue to communicate with ... Equitable IP and our due diligence on other patent ...
(Date:1/23/2017)... , Jan. 23, 2017  Alkahest Inc. ... treatments for neurodegenerative diseases and other age-related conditions, ... the company as Chief Medical Officer. In this ... clinical development activities at Alkahest and serve on ... most recently served as Executive Director at Dynavax, ...
Breaking Biology Technology:
(Date:1/19/2017)... January 19, 2017 According to a new report published ... 2014 - 2022," the global biometric sensor market is expected to garner $1.5 ... In 2015, Asia-Pacific dominated the global market and contributed ... Continue Reading ... ...
(Date:1/18/2017)... MINNETONKA, Minn. , Jan. 18, 2017 /PRNewswire/ ... eClinical technology company that supports the entire spectrum ... 2016 has been another record-breaking year for the ... and market interest in MedNet,s eClinical products and ... to the tremendous marketplace success of ...
(Date:1/12/2017)... 12, 2017  New research undertaken by Fit Small ... future.  1,000 participants were simply asked which office technology had ... may consider standard issue.  Insights on what will ... gathered from futurists and industry leaders including Penelope Trunk ... .  Some of these findings ...
Breaking Biology News(10 mins):